Opus Genetics, Inc. 8-K Filings

Opus Genetics, Inc. (IRD) reported interim 3‑ and 6‑month data from low‑dose Cohort 1 of its Phase 1/2 BIRD‑1 trial of gene therapy OPGx‑BEST1 in BEST1‑related retinal diseases. Five adults received 1.5 x 10⁹ vg/eye; all showed clinically meaningful improvement in at least one visual‑function measure, and four showed structural retinal improvements.

OPGx‑BEST1 was well tolerated, with no serious adverse events, dose‑limiting toxicities or intraocular inflammation; all treatment‑related events were mild or moderate. Functional gains included BCVA improvement in 60% of participants, and microperimetry improvements in 75% of evaluable participants, concentrated in the treated retinal transitional zone. Based on these proof‑of‑concept results, Opus has advanced to a higher‑dose Cohort 2 (4.5 x 10⁹ vg/eye), over‑enrolled to eight participants, with dosing expected to complete in Q4 2026 and topline three‑month data expected in Q2 2027. Following an August 2026 FDA Type C meeting, Opus and the FDA aligned on a potential pivotal endpoint using ≥3 dB microperimetry improvement in ≥5 prespecified loci with a patient‑reported outcome, and Opus expects to plan Phase 3 dosing in 2027. New research estimates about 23,600 symptomatic BEST1 patients in the U.S. and 45,400 globally, and the company states its cash runway extends into 2029.

Opus Genetics reported second-quarter 2026 license and collaborations revenue of $0.8 million, down from $2.9 million a year earlier. Research and development expenses rose to $11.2 million and general and administrative expenses were $6.0 million, leading to a loss from operations of $16.5 million. After a $7.2 million fair value gain on instruments and $1.7 million of other income, net loss was $8.1 million, or ($0.08) basic and ($0.14) diluted per share.

As of June 30, 2026, cash and cash equivalents were $88.8 million, compared with $45.1 million at year-end 2025. With this balance and potential future fundings under its Oberland Capital note purchase agreement, the company expects its cash resources to fund operations into 2029. Total liabilities were $106.0 million, including $34.9 million of long-term debt and $62.1 million of warrant liabilities, contributing to stockholders’ equity of $(13.0) million.

Clinically, Opus completed enrollment in Cohort 1 of its OPGx-BEST1 Phase 1/2 trial, with 3‑month topline data targeted for the second week of September 2026. Enrollment is also complete in the registrational OPGx-LCA5 Phase 3 trial, with dosing expected in the fourth quarter of 2026 and topline data anticipated by the end of 2027. Additional gene therapy programs targeting RDH12, MERTK and RHO are expected to enter clinical testing between late 2026 and the second half of 2027.

Opus Genetics, Inc. reported on its expanding pipeline of gene therapies for inherited retinal diseases after hosting a Research and Development Science Forum. The company highlighted five IRD programs, with four clinical data readouts expected in 2027, and said RDH12, MERTK and RHO programs are expected to enter clinical testing over the next 12 to 18 months.

Management stated that its cash runway extends into 2029 and is expected to fund multiple clinical inflection points and potential product approvals, as well as opportunities for Priority Review Vouchers. Opus Genetics’ pipeline includes seven AAV-based programs, led by OPGx-LCA5 and OPGx-BEST1, targeting severe inherited retinal disorders.

Opus Genetics, Inc. furnishes an investor presentation from its Virtual R&D Science Forum, outlining its inherited retinal disease (IRD) gene therapy strategy and pipeline. The company highlights seven AAV-based programs targeting LCA5, BEST1, RDH12, MERTK, RHO, NMNAT1 and CNGB1, with worldwide rights to all programs.

Management states Opus is fully funded into 2029 to advance five IRD clinical programs through potential product approvals and Priority Review Voucher opportunities. Key near-term milestones include a PDUFA date in October 2026 for a partnered phentolamine sNDA, BEST1 Cohort 1 three‑month results in September 2026, Phase 3 dosing for LCA5 in Q4 2026, and initial RDH12 and MERTK clinical study initiations between Q4 2026 and Q1 2027. Four clinical data readouts are expected in 2027.

The presentation details disease biology, prevalence and preclinical data for RDH12, MERTK, RHO, LCA5 and BEST1, along with patient‑reported outcomes from the OPGx‑LCA5 study showing maintained or improved visual acuity and functional vision gains in small adult and pediatric cohorts. Opus also emphasizes global IRD prevalence, strategic partnerships for trial recruitment, and a dose‑exploration, data‑driven clinical development approach.

Opus Genetics reported first-quarter 2026 results and highlighted major pipeline progress in inherited retinal disease gene therapies. License and collaboration revenue was $2.2 million, down from $4.4 million a year earlier, reflecting lower reimbursed R&D activity. R&D expenses rose to $10.6 million while G&A declined slightly to $5.9 million.

Net loss widened sharply to $65.5 million, or $0.75 per share, mainly due to a large non-cash fair value loss on warrant liabilities, along with higher R&D spending. Cash and cash equivalents were about $60 million on March 31, 2026, and a new financing with Oberland Capital includes $35 million in senior secured notes and a planned $5 million equity investment. The company believes its current and potential funding will support operations into 2029.

Clinically, Opus reported strong six‑month pediatric data for OPGx-LCA5, FDA acceptance of LCA5 into the Rare Disease Evidence Principles program, and plans to start pivotal Phase 3 dosing in the fourth quarter of 2026. Topline Cohort 1 data for OPGx-BEST1 are expected in September 2026, while RDH12, MERTK, and RHO programs are slated to reach the clinic over the next one to two years.

Opus Genetics, Inc. entered into a senior secured note purchase agreement that allows issuance of up to $155 million in senior secured notes. Purchasers have committed to $105 million, with an additional $50 million uncommitted and available upon meeting conditions and milestones.

The initial tranche of $35 million was funded at par on April 21, 2026, with these notes maturing on April 21, 2033. The notes bear floating interest based on Term SOFR, subject to a floor, plus a margin, paid quarterly. They are secured by substantially all company and subsidiary assets and guaranteed by certain subsidiaries, with obligations subject to customary events of default.

Opus Genetics, Inc. held its 2026 annual stockholder meeting, where stockholders approved all proposals on the ballot. They elected nine directors to one-year terms, with each nominee receiving over 33.8 million votes in favor and more than 12 million broker non-votes recorded.

Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, by 46,844,680 votes for versus 315,324 against. They also approved, on an advisory basis, executive compensation and passed an amendment to increase authorized common stock from 125 million to 250 million shares, with 45,360,642 votes for, 1,486,247 against, and 429,479 abstentions.

Opus Genetics, Inc. entered into Change in Control Bonus Payment Agreements on April 1, 2026 with its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, and Chief Scientific and Development Officer. These agreements provide that the company will reimburse each executive for any excise taxes incurred under Section 4999 of the Internal Revenue Code in connection with a change in control of the company.

The agreements are based on a common form, which is filed as Exhibit 10.1 and incorporated by reference, giving investors access to the full contractual terms around potential change-in-control-related tax reimbursements for the senior leadership team.

Opus Genetics entered a senior secured note purchase agreement with Oberland Capital affiliates providing for up to $155 million of non-dilutive funding, with an initial $35 million tranche expected at the April 20, 2026 closing and additional tranches tied to time-based and FDA milestones for OPGx-LCA5.

The notes mature on April 2, 2033, carry floating interest based on Term SOFR with a 3.68% floor plus margin, and feature six years of interest-only payments, partial paid-in-kind interest for the first eight quarters of each tranche, and a 50% principal amortization on the sixth anniversary of the first purchase date. Up to 10% of each purchaser’s principal may be converted into common stock at $6.72 per share.

Opus also agreed to sell 1,116,070 common shares at $4.48 per share for an aggregate $4,999,994 and grant price-protection options on additional shares if a future dilutive equity round occurs. The company reports approximately $100 million in cash including the initial note and equity funding and states this extends its runway into 2029 to support pivotal OPGx-LCA5 and OPGx-BEST1 studies and broader pipeline development.

Opus Genetics reported full-year 2025 results alongside a broad pipeline update. License and collaboration revenue reached $14.2 million, up from $11.0 million in 2024, driven by R&D reimbursement from its Viatris collaboration. R&D expenses rose to $30.8 million and G&A expenses to $22.0 million, reflecting higher clinical, payroll, legal, and public company costs.

The company posted a net loss of $49.6 million, or ($0.80) per share, improving from a $57.5 million loss, mainly due to the absence of a $28.0 million acquired in‑process R&D charge recorded in 2024, partly offset by an $11.5 million increase in warrant and derivative liabilities. Cash and cash equivalents were $45.1 million at December 31, 2025, and a subsequent private placement raised about $25.0 million, giving aggregate cash resources of $70.1 million that are expected to fund operations into the first half of 2028.

Operationally, Opus highlighted favorable early safety and initial efficacy data from its OPGx‑BEST1 gene therapy, positive clinical results from its OPGx‑LCA5 program, and funding for its MERTK program. It also noted a Prescription Drug User Fee Act (PDUFA) decision date in October 2026 for Phentolamine Ophthalmic Solution 0.75% in presbyopia and emphasized that reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher program could benefit its rare inherited retinal disease pipeline.

Opus Genetics, Inc. completed a $25.0 million private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock at $3.39 per share. These preferred shares are non-voting, rank on parity with common stock in a liquidation, and receive dividends as if converted to common.

Each preferred share will automatically convert into one share of common stock after stockholders approve an increase in authorized common shares at the 2026 annual meeting, subject to holder-set ownership caps between 0% and 19.9% of outstanding common stock. The company also granted investors registration rights to resell the common shares issuable upon conversion.

Opus Genetics plans to use the proceeds to advance its gene therapy clinical programs, working capital, and general corporate purposes. It reported preliminary cash of $45 million as of December 31, 2025, and a pro forma cash balance of $70 million after giving effect to the financing, with the year-end figures still unaudited and subject to adjustment.

Opus Genetics, Inc. is highlighting its business at the 44th Annual J.P. Morgan Healthcare Conference, where management will deliver a corporate presentation on January 15, 2026 at 8:15 a.m. Pacific Time. A live webcast of the talk will be available through the company’s investor relations website, allowing investors to listen remotely. The associated January 2026 corporate presentation is provided as Exhibit 99.1 and is also posted in the “Overview” section of the company’s investor site.

Opus Genetics, Inc. furnished a current report to share a new corporate update with investors. The company submitted an 8-K that includes a press release titled “Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts,” indicating it has summarized recent achievements from 2025 and outlined important expected milestones for 2026. The information is provided under a disclosure item that is treated as “furnished” rather than “filed,” meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.

Opus Genetics, Inc. reported that it has released its financial results for the third quarter ended September 30, 2025, and has shared these details through a press release.

The company furnished this press release as Exhibit 99.1 to a current report, allowing investors to review the full quarterly results and commentary there. The information in this report and the exhibit is treated as furnished rather than filed under the securities laws, which affects how it is incorporated into other regulatory filings.

Opus Genetics entered a securities purchase agreement for a registered direct offering, selling 3,827,751 shares of common stock and issuing pre-funded warrants for 7,177,033 shares. Shares are priced at $2.09 and the pre-funded warrants at $2.0899 (with a $0.0001 exercise price). Gross proceeds are expected to be approximately $23.0 million, with closing expected on or about November 7, 2025, subject to customary conditions.

The company plans to use net proceeds to advance its LCA5 and BEST-1 gene therapy clinical programs and for working capital and general corporate purposes. The transaction was conducted without a placement agent or underwriter, so no underwriting discounts or commissions are being paid. The pre-funded warrants are immediately exercisable and include a beneficial ownership cap of 4.99% (or 9.99% at holder election). The securities were offered under the company’s effective Form S-3 (File No. 333-276462).

Opus Genetics (IRD) filed an 8‑K announcing a $23 million registered direct offering and the successful completion of a Type B RMAT meeting with the FDA for OPGx‑LCA5, its gene therapy for LCA5‑related blindness. The FDA provided constructive feedback on Chemistry, Manufacturing and Controls and pivotal trial design and acknowledged the significant unmet medical need, noting regulatory flexibility for rare genetic diseases.

In Phase 1/2, six late‑stage participants treated with OPGx‑LCA5 experienced clinically meaningful vision improvements. The Phase 3 portion is planned as a single‑arm, 12‑month, adaptive study enrolling as few as eight participants, with a run‑in to establish each participant’s natural history as their own control. Dosing is anticipated in the second half of 2026 after validated commercial‑process supply, with topline data expected about one year later. Including expected offering proceeds, the company projects cash resources funding operations into the second half of 2027.

Opus Genetics reported encouraging early results from its Phase 1/2 OPGx-LCA5-1001 trial of OPGx-LCA5, a gene therapy for Leber congenital amaurosis type 5. The treatment has been well tolerated in all six participants (three adults and three pediatric), with no ocular serious adverse events or dose-limiting toxicities and only mild, expected eye-related side effects not attributed to the study drug.

All three pediatric participants with severe baseline vision impairment showed improvements across several vision measures after a single subretinal injection, including an average 0.3 logMAR gain in visual acuity and more than a 1 log unit increase in cone sensitivity to red and blue light, alongside mobility and microperimetry benefits. In adults, improvements in visual acuity were sustained through 18 months. The company plans to meet with the U.S. Food and Drug Administration in the fourth quarter of 2025 to discuss these results and potential next steps for the program.